| Literature DB >> 18670651 |
Guldem Kilciler1, Ugur Musabak, Sait Bagci, Zeki Yesilova, Ahmet Tuzun, Ahmet Uygun, Mustafa Gulsen, Sema Oren, Cagatay Oktenli, Necmettin Karaeren.
Abstract
BACKGROUND: Acute pancreatitis is the major complication of endoscopic retrograde cholangiopancreatography (ERCP) procedure and there are some reports showing cytokine changes in ERCP-induced pancreatits. GOALS: To investigate the association between early changes (within 24 hours) in the serum interleukin (IL)-2, IL-4, tumor necrosis factor (TNF)alpha, and IL-6 levels and the development of post-ERCP pancreatitis. STUDY: Forty five consecutive patients who underwent therapeutic ERCP and 10 patients with acute pancreatitis without ERCP were enrolled to the study. Serum concentrations of IL-2, IL-4, TNFalpha, and IL-6 were determined immediately before, 12 hours and 24 hours after ERCP.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18670651 PMCID: PMC2486352 DOI: 10.1155/2008/481560
Source DB: PubMed Journal: Clin Dev Immunol ISSN: 1740-2522
Exclusion and inclusion criteria of the patients.
| Exclusion criteria | Inclusion criteria |
|---|---|
| Emergency ERCP | Choledocholithiasis |
| Previous therapeutic ERCP | Pancreato-biliary malignancy |
| Previous surgery of the upper GI tract | Cholestasis of unknown origin |
| Acute pancreatitis at time of study | Cholangitis |
| Known history of chronic pancreatitis | Tumor of papilla |
| Less than 18 years of age | Others |
| Known history of mental disease | |
| Unable to give informed consent | |
| Female who is pregnant | |
| Underlying chronic liver disease | |
| Abnormal coagulation tests (PTT < 75% or INR > 1.5 or APTT > 35) | |
| Immunocompromized patients |
Comparisons of IL-2, IL-4, TNFα, IL-6, CRP and amylase levels and IL-2/IL-4 and TNFα/IL-4 ratios in the patients who underwent ERCP and control group with acute pancreatitis without ERCP.
| Patients with post-ERCP pancreatitis ( | Patients without pancreatitis ( | Patients with acute pancreatitis without ERCP ( | |||||
|---|---|---|---|---|---|---|---|
| Time (hour) |
|
|
|
|
|
| |
| IL-2 (pg/mL) | 15.6 (19.9) | 14.3 (14.1) | 12.7 (15.5) | 15.1 (43.9) | 12.7 (76.0) | 15.1 (46.0) | 11.4 (13.0) |
| IL-4 (pg/mL) | 29.0 (69.1) | 63.6 (67.5) |
| 37.7 (146.8) | 55.9 (83.8) |
|
|
| TNF | 20.2 (67.8) |
| 44.9 (77.5) |
|
| 51.8 (72.1) |
|
| IL-6 (pg/mL) |
|
|
|
|
|
|
|
| IL-2/IL-4 | 0.62 (2.03) | 0.33 (2.30) | 0.40 (0.90) | 0.44 (26.81) | 0.24 (2.61) | 0.23 (0.71) | 0.3 (0.61) |
| TNF | 0.56 (10.0) |
|
| 0.67 (91.83) |
|
| 1.0 (1.53) |
| CRP (mg/dL) | 10.2 (49) | 17.0 (33) | 10 (47) | 3.9 (212) | 8.0 (395) | 6.7 (342) | 12.0 (42) |
| Amylase (U/mL) |
|
|
|
|
|
|
|
P values: .010 for (a) versus (b); .025 for (b) versus (c); .002 for (d) versus (e); .011 for (f) versus (g); .001 for (h) versus (i); <.001 for (j) versus (i); .014 for (k) versus (i); .012 for (l) versus (i); .034 for (m) versus (n); .001 for (n) versus (i); .028 for (o) versus (p); .041 for (r) versus (s); .001 for (t) versus (u); <.001 for (v) versus (u); <.001 for (x) versus (y); <.001 for (y) versus (u); <.001 for (z) versus (zz); <.001 for (zz) versus (u); .001 for (z) versus (u).
Figure 1The levels of IL-4 (a) and TNF (b), (c), IL-6 (d), (e), (f) and the ratios of TNF/IL-4 (g), (h) in the patients with ERCP-induced pancreatitis (EIP+), patients without ERCP induced pancreatitis (EIP−), and the control group (CG) with acute pancreatitis without ERCP. Boxes show the ranges of 1st and 3rd quartiles and extreme values. Horizontal bars represent median values. The differences between two groups were evaluated by Mann-Whitney U test. P values were indicated above the boxes when a level of significance less than or equal to .05 was reached in comparisons of study groups.
Figure 2Serial concentrations of IL-2, IL-4, TNF and IL-6 before and within 24 hours after ERCP in the patients (a) with post-ERCP pancreatits and (b) without pancreatitis. Bars represent mean ± 95% CI. The differences between two groups were evaluated by Mann-Whitney U test. P values were indicated above the boxes when a level of significance less than or equal to .05 was reached in comparisons of study groups.